Business and Finance

Facility meets cGMP standards for radiopharmaceutical production

CDTMO’s fourth site further expands its support of cell therapy delivery and access

Transaction enhances CDMO’s services when it comes to drug product offerings

Research collaboration centered around AAV capsids

Deal is expected to boost manufacturer’s European presence, Aceto executives say

Among areas, financial commitment will power clinical and commercial manufacturing suites

Company officials predict 500 million vaccine doses per year to be produced via the center, which will offer fill-finish, packaging services

Previous merger earns clinical research company $235 million as it looks to advance patient enrollment

Company officials believe new facility will help meet ongoing demand for temperature-controlled packaging

Using AI and data engineering insight, purchase offers customers potential to shorten clinical trials and accelerate time to commercialization

Manufacturing facility to provide 1.5 million square feet of bioproduction technologies

Will feature laboratories intended for R&D

Collaboration centers around providing assistance to multiple links in the clinical trial chain, from participants to providers

Development of additional 29,000 square feet addresses med tech company’s internal production capabilities

Recent FDA actions may finally usher in access boost to follow-on biologics in the US

R&D partnership with VaxEquity outlines plan to use saRNA as a go-to therapeutic

Availability of space for new labs is a key selling point

Acquisition expected to help provide customers with a quicker clinical trial recruitment process

Five-year, nearly $90 million deal revolves around bulk drug substance formulation for Providence’s future shot

Latest construction plan continues CDMO’s vision for biopharma expansion

Collaboration earns Adaptimmune an initial payday of $150 million

Supply deal with Takeda to begin distribution in early 2022, pending shot approval

Drug maker to supply European Union with 60 million doses by end of Q3

Swiss organization will take patient-centric approach towards developing injectables

Agreement will focus on developing, manufacturing and commercializing biosimilars in the respiratory space